Before Invest
PFIZER INC logo

PFIZER INC

PFE
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 28, 2026
Financial Statements Ratios
Export XLSX
Unlock 40 quarters
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		Jun 28, 2026Mar 29, 2026Sep 28, 2025Jun 29, 2025Mar 30, 2025Sep 29, 2024Jun 30, 2024Mar 31, 2024Oct 1, 2023Jul 2, 2023Apr 2, 2023Oct 2, 2022Jul 3, 2022Apr 3, 2022Oct 3, 2021Jul 4, 2021Apr 4, 2021Sep 27, 2020Jun 28, 2020Mar 29, 2020Sep 29, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jul 1, 2018Apr 1, 2018Oct 1, 2017Jul 2, 2017Apr 2, 2017Oct 2, 2016Jul 3, 2016Apr 3, 2016Sep 27, 2015Jun 28, 2015Mar 29, 2015Sep 28, 2014Jun 29, 2014Mar 30, 2014Sep 29, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jul 1, 2012Apr 1, 2012Oct 2, 2011Jul 3, 2011Apr 3, 2011Oct 3, 2010Jul 4, 2010Apr 4, 2010Sep 27, 2009Jun 28, 2009
Alliance revenues
$ 2,697
$ 2,339
$ 2,298
$ 2,273
$ 2,113
$ 1,900
$ 2,067
$ 2,172
-
-
-
-
Total revenues
15,034
14,451
16,654
14,653
13,715
17,702
13,283
14,879
13,232
12,734
18,282
-
Revenues
-
-
-
-
-
-
-
-
-
-
-
22,638
Costs and expenses:
                                                    
Cost of sales
4,092
3,548
4,172
3,778
2,845
5,263
3,300
3,379
9,269
3,237
4,886
6,063
Selling, informational and administrative expenses
3,411
2,961
3,186
3,415
3,031
3,244
3,717
3,495
3,281
3,497
3,418
3,391
Research and development expenses
2,809
2,490
2,546
2,482
2,203
2,598
2,696
2,493
2,711
2,648
2,505
2,696
Acquired in-process research and development expenses
16
137
1,390
2
9
13
6
0
67
33
21
524
Amortization of intangible assets
1,185
1,183
1,223
1,211
1,211
1,312
1,307
1,308
1,179
1,184
1,103
822
Acquisition-related in-process research and development charges
-
-
-
-
-
-
-
-
-
-
-
-
Restructuring charges and certain acquisition-related costs
457
100
286
(18)
678
313
1,254
102
155
214
9
199
(Gain) on completion of Consumer Healthcare JV transaction
-
-
-
-
-
-
-
-
-
-
-
-
Other (income)/deductions––net
(3,716)
(861)
(517)
(739)
(953)
(243)
(1,107)
(680)
79
347
(70)
59
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)
(653)
3,170
3,334
3,044
2,785
4,715
(103)
3,421
(3,352)
2,269
6,270
9,001
Other deductions - net
-
-
-
-
-
-
-
-
-
-
-
-
Provision/(benefit) for taxes on income/(loss)
(407)
461
(216)
141
(189)
234
(134)
293
(964)
(71)
715
356
Income/(loss) from continuing operations
(246)
2,709
3,550
2,903
2,973
4,481
31
3,128
(2,388)
2,340
5,555
8,645
Discontinued operations:
                                                    
Income from discontinued operations––net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Gain on disposal of discontinued operations––net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Discontinued operations––net of tax
8
(13)
0
25
0
(8)
17
(5)
12
(2)
1
(21)
Net income/(loss) before allocation to noncontrolling interests
(237)
2,696
3,550
2,928
2,973
4,473
48
3,123
(2,376)
2,338
5,556
8,623
Less: Net income attributable to noncontrolling interests
10
8
9
18
6
8
7
8
6
11
13
15
Net income/(loss) attributable to Pfizer Inc. common shareholders
$ (248)
$ 2,687
$ 3,541
$ 2,910
$ 2,967
$ 4,465
$ 41
$ 3,115
$ (2,382)
$ 2,327
$ 5,543
$ 8,608
Earnings/(loss) per common share––basic:
                                                    
Income /loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
$ (0.04)
$ 0.48
$ 0.62
$ 0.51
$ 0.52
$ 0.79
$ 0.01
$ 0.55
$ (0.42)
$ 0.41
$ 0.98
$ 1.54
Discontinued operations––net of tax (in dollars per share)
0
0
0
0
0
0
0
0
0
0
0
0
Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share)
(0.04)
0.47
0.62
0.51
0.52
0.79
0.01
0.55
(0.42)
0.41
0.98
1.54
Earnings/(loss) per common share––diluted:
                                                    
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
(0.04)
0.47
0.62
0.51
0.52
0.79
0.01
0.55
(0.42)
0.41
0.97
1.51
Discontinued operations––net of tax (in dollars per share)
0
0
0
0
0
0
0
0
0
0
0
0
Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share)
(0.04)
0.47
0.62
0.51
0.52
0.78
0.01
0.55
(0.42)
0.41
0.97
1.51
Weighted-average shares used to calculate earnings per common share:
                                                    
Weighted-average shares--basic (in shares)
5,699
5,691
5,685
5,685
5,675
5,667
5,666
5,657
5,646
5,646
5,634
5,607
Weighted-average shares--diluted (in shares)
5,699
5,731
5,714
5,706
5,710
5,705
5,696
5,697
5,646
5,713
5,727
5,718
Cash dividends paid per common share (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
-